Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C

Thyroid

Volumn 23, Issue 9, 2013, Pages 1151-1158

  Mammen, Jennifer S ^a   Ghazarian, Sharon R ^a   Rosen, Antony ^a   Ladenson, Paul W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; THYROTROPIN; THYROXINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HUMAN SERUM ALBUMIN-INTERFERON-ALPHA-2B FUSION PROTEIN; HYBRID PROTEIN; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; SERUM ALBUMIN;

ADULT; ARTICLE; ASIAN; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; SMOKING; THYROID DISEASE; THYROIDITIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; ADVERSE EFFECTS; ANCESTRY GROUP; ASIA; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; EPIDEMIOLOGY; ETHNOLOGY; EUROPE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NORTH AMERICA; RISK; SOUTH AMERICA; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; ASIA; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CONTINENTAL POPULATION GROUPS; EUROPE; FEMALE; HEPATITIS C; HUMANS; HYPOTHYROIDISM; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NORTH AMERICA; ODDS RATIO; POLYETHYLENE GLYCOLS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; RISK FACTORS; SERUM ALBUMIN; SEX FACTORS; SMOKING; SOUTH AMERICA; THYROIDITIS; THYROTROPIN; THYROXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884131164     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0565     Document Type: Article

References (40)

1. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH 1992 Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102:2155-2160.
2. Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M 1999 HLA antigens in patients with interferon-alphainduced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 30:794-800.
3. Antonelli A, Ferri C, Fallahi P 2009 Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 6:633-635.
4. Pavan MH, Pavin EJ, Goncales FL Jr, Wittmann DE 2011 Virus C genotype predisposes to primary hypothyroidism during interferon-alpha treatment for chronic hepatitis C. Braz J Infect Dis 15:449-456.
5. Vasiliadis T, Anagnostis P, Nalmpantidis G, Soufleris K, Patsiaoura K, Grammatikos N, Orfanou-Koumerkeridou E, Kargiotis K, Slavakis A, Deliyiannidis A, Eugenidis N 2011 Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C. Ann Acad Med Singapore 40:394-400.
6. Huang JF, Huang CK, Yu ML, Dai CY, Huang CF, Hung WW, Yeh ML, Hsieh MH, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wu SS, Chuang WL 2012 Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. Hepatol Int 6:613-619.
7. Costelloe SJ, Wassef N, Schulz J, Vaghijiani T, Morris C, Whiting S, Thomas M, Dusheiko G, Jacobs M, Vanderpump MP 2010 Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy. Clin Endocrinol (Oxf ) 73:249-256.
8. Mammen JS, Ghazarian SR, Pulkstenis E, Subramanian GM, Rosen A, Ladenson PW 2012 Phenotypes of interferonalpha-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex. J Clin Endocrinol Metab 97:3270-3276.
9. Tran HA, Reeves GE, Ianna EA, Leembruggen N 2010 Thyroid function outcomes after pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Endocr Pract 16:934-939.
10. Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C 2009 Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 15:328-333.
11. Jamil KM, Leedman PJ, Kontorinis N, Tarquinio L, Nazareth S, McInerney M, Connelly C, Flexman J, Burke V, Metcalf C, Cheng W 2009 Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol 24:1017-1023.
12. Nadeem A, Aslam M, Khan DA, Hussain T, Khan SA 2009 Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C. J Coll Physicians Surg Pak 19:86-89.
13. Tran HA, Malcolm Reeves GE, Gibson R, Attia JR 2009 Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a metaanalysis. J Gastroenterol Hepatol 24:1163-1168.
14. Andrade LJ, Atta AM, D'Almeida A Jr, Parana R 2008 Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin-a review. Braz J Infect Dis 12:144-148.
15. Masood N, Ghori R, Memon A, Memon S, Memon KI, Memon I, Jaffri M, Baloch GH 2008 Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection. J Coll Physicians Surg Pak 18:347-351.
16. Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, Lachkar H, Benaissa A 2006 Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris) 67:343-347.
17. Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN, Wang PW 2006 Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol 21:319-326.
18. Caraccio N, Giannini R, Cuccato S, Faviana P, Berti P, Galleri D, Dardano A, Basolo F, Ferrannini E, Monzani F 2005 Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 90:1156-1162.
19. Moncoucy X, Leymarie F, Delemer B, Levy S, Bernard-Chabert B, Bouche O, Jolly D, Diebold MD, Cadiot G, Thiefin G 2005 Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 29:339-345.
20. Bini EJ, Mehandru S 2004 Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 164:2371-2376.
21. Dalgard O, Bjoro K, Hellum K, Myrvang B, Bjoro T, Haug E, Bell H 2002 Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med 251:400-406.
22. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY, Chang WY 2000 Virologic factors related to interferon-alpha- induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 142:431-437.
23. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S 1997 Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 26:206-210.
24. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489-499.
25. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE 2007 National Health and Nutrition Examination Survey III thyroid-stimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab 92:4236-4240.
26. Tomer Y 2010 Hepatitis C and interferon induced thyroiditis. J Autoimmun 34:J322-J326.
27. Andersson M, Takkouche B, Egli I, Allen HE, de Benoist B 2005 Current global iodine status and progress over the last decade towards the elimination of iodine deficiency. Bull World Health Organ 83:518-525.
28. de Benoist B, McLean E, Andersson M, Rogers L 2008 Iodine deficiency in 2007: global progress since 2003. Food Nutr Bull 29:195-202.
29. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG, ACHIEVE-2/3 Study Team 2010 Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 139:1267-1276.
30. Akeno N, Smith EP, Stefan M, Huber AK, Zhang W, Keddache M, Tomer Y 2011 IFN-alpha mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol 186:4693-4706.
31. Menconi F, Hasham A, Tomer Y 2011 Environmental triggers of thyroiditis: hepatitis C and interferon-alpha. J Endocrinol Invest 34:78-84.
32. Vestergaard P 2002 Smoking and thyroid disorders-a metaanalysis. Eur J Endocrinol 146:153-161.
33. Belin RM, Astor BC, Powe NR, Ladenson PW 2004 Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 89:6077-6086.
34. Asvold BO, Bjoro T, Nilsen TI, Vatten LJ 2007 Tobacco smoking and thyroid function: a population-based study. Arch Intern Med 167:1428-1432.
35. Pedersen IB, Laurberg P, Knudsen N, Jorgensen T, Perrild H, Ovesen L, Rasmussen LB 2008 Smoking is negatively associated with the presence of thyroglobulin autoantibody and to a lesser degree with thyroid peroxidase autoantibody in serum: a population study. Eur J Endocrinol 158:367-373.
36. KitaharaCM, LinetMS, Beane Freeman LE, CheckDP, Church TR, Park Y, PurdueMP, Schairer C, Berrington de Gonzalez A 2012 Cigarette smoking, alcohol intake, and thyroid cancer risk: a pooled analysis of five prospective studies in the United States. Cancer Causes Control 23:1615-1624.
37. Caturegli P, De Remigis A, Ferlito M, Landek-Salgado MA, Iwama S, Tzou SC, Ladenson PW 2012 Anatabine ameliorates experimental autoimmune thyroiditis. Endocrinology 153:4580-4587.
38. Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, Yang F, Dai H, Yu Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, Tong Y, Wang W, Gao T, Li C 2006 Effect of iodine intake on thyroid diseases in China. N Engl J Med 354:2783-2793.
39. Teng X, Shan Z, Chen Y, Lai Y, Yu J, Shan L, Bai X, Li Y, Li N, Li Z, Wang S, Xing Q, Xue H, Zhu L, Hou X, Fan C, Teng W 2011 More than adequate iodine intake may increase subclinical hypothyroidism and autoimmune thyroiditis: a cross-sectional study based on two Chinese communities with different iodine intake levels. Eur J Endocrinol 164:943-950.
40. Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG 2001 Iodine-induced hypothyroidism. Thyroid 11:501-510. Diseases